---
title: 4Q 2019 Results and preliminary annual report
description: "4Q 2019 Results and preliminary annual report
Moss, 14 February 2020 

Gentian Diagnostics AS announces its results for the 4th quarter and 2019 preliminary annual results."
---

Moss, 14 February 2020

 

Gentian Diagnostics AS announces its results for the 4th quarter and 2019 preliminary annual results.

 

The highlights include:

 

- Record sales revenues of MNOK 14.1 in 4Q19, up from MNOK 11.1 in 4Q18, totaling a 27 % growth y/y
- Total sales revenue for the year of MNOK 48.0 representing 20 % growth compared to 2018
- Strong fCAL® turbo sales in Q4 resulting in a y/y growth of 112% driven by continued growth in kit sales and positive effect from bulk orders
- fPELA development completed. External validation ongoing 

Please find the report and results presentation enclosed here:

[14th Feb 2020 - Quarterly Report - Q4](https://www.gentian.com/hubfs/14th%20Feb%202020%20-%20Quarterly%20Report%20-%20Q4.pdf)

[14th Feb 2020 - Quarterly Presentation - Q4](https://www.gentian.com/hubfs/14th%20Feb%202020%20-%20Quarterly%20Presentation%20-%20Q4.pdf)

 

**For further information, please contact: **

Hilja Ibert CEO, Gentian Diagnostics

E-mail: [hilja.ibert@gentian.no ](mailto:hilja.ibert@gentian.no)

Cell Phone: +47 919 05 242

 

Njaal Kind CFO, Gentian Diagnostics

E-mail: [njaal.kind@gentian.no ](mailto:njaal.kind@gentian.no)

Cell Phone. +47 919 06 525

 

**MeldingsID:** 495485

**UtstederID:** GENT-ME

**Marked:** Merkur Market

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/14th-feb-2020-quarterly-report-q4#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/14th-feb-2020-quarterly-report-q4#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/14th-feb-2020-quarterly-report-q4#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)